was perfectly well. Dr Gloor was emboldened to publish this case, and one might have thought that he would have been acclaimed as a national hero in Switzerland. Instead, he was fired from his job in Naegeli's clinic and was banished to a clinic in one of the outlying cantons, where he spent the rest of his career. I have actually spoken to those who knew him and they have vouched for this account. Everyone then knew that acute leukemia was always fatal, and that anyone who thought that he had cured a case must be either a fool or a knave.
I called attention to this case in the early 1980s in an article I wrote for JAMA, 3 and I was delighted to receive a letter from Dr H Gruenwald, a hematologist who worked in New York. Dr Gruenwald wrote that he thought I might be interested in a follow-up. ' The patient', he wrote to me, 'was Eugene Metzger, a great uncle of his wife's. He had continued his successful business in the lace industry after his return from Naegeli's clinic and became a well-known philanthropist in New York. The administration building at Mount Sinai Medical School is named after him and his wife, Rose. At the time of their wedding in 1968, at the age of 80, Mr Metzger gleefully recounted his experience of being brought back from the gates of death, and he died at the ripe old age of 102, about 50 years after he had been seen by Dr Gloor'. It is possible that Mr Metzger was not cured, but it was a very long remission. Arsenic, one of the components of RAT, continued to play a role in the treatment of leukemia for quite a long time. We used to think, even in the 1950s and 1960s, that the use of arsenic in the treatment of leukemia was really quite quaint. But it now appears that arsenic has a very real effect in the treatment of promyelocytic leukemia. A recent paper in Blood 4 described how complete clinical remissions were obtained in eight of 11 patients. There are now many studies that examine the molecular mechanism by which arsenic may produce this effect in promyelocytic leukemia.
In 1948, Sidney Farber reported the first rational treatment for acute leukemia. 5 Aware of anecdotal evidence that children with acute leukemia who were given the then-new vitamin, folic acid, became worse, Farber reasoned that if folic acid metabolism could be blocked that perhaps they would improve. He gave children aminopterin, a folic acid inhibitor. In publishing his promising results, he wrote 'we may now with some justice hope that aminopterin, or some as yet unsynthesized substance related to it, will afford a substantial basis for real hope in this now hopeless disease'.
Nonetheless, the outlook in acute leukemia remained very gloomy through the 1950s and the 1960s. In the 1960s Boggs, Wintrobe, and Cartwright reviewed the acute leukemias and discussed the response to therapy, which then consisted of 6-mercaptopurine (6-MP) and methotrexate. They pointed out that only one in five patients improved with 6-MP, which coincides with my own experience in those days. They stated that, 'the possibility of spontaneous remission must be entertained whenever a patient with acute leukemia becomes apparently well yet, so far as known, practically all such patients subsequently died in relapse. Of the extremely rare case in which the patient did not die, it may be said that the original diagnosis was incorrect'. 6 Of course, this is a selffulfilling prophecy. If one assumes that the diagnosis is incorrect for any patient who recovers, then no patient with that diagnosis will ever recover.
Among children, the situation actually began to improve very largely as a result of the systematic studies that were carried out by Don Pinkel and his associates at St Jude's. 7 A recent summary of the children that were treated from 1962 to 1966, then from 1967 to 1979 with a new protocol, and then from 1984 to 1988 with yet another, refined protocol show that the systematic modification of chemotherapeutic programs in children produced a very gratifying and even astonishing improvement in this hitherto almost always fatal disorder.
Yet, in adults the prognosis of acute leukemia continued to be nearly hopeless. I had the opportunity to treat many patients with acute leukemia in the 1950s and 1960s. As a matter of fact, when I became a faculty member at the University of Chicago, the first referral specifically to me was of a patient with acute leukemia. It was from a physician friend of my father's, who was a physician in Milwaukee. I was very proud to have a patient referred specifically to me, but in 3 days the patient was dead. That was not unusual, and physicians did not cover themselves with glory in caring for patients with leukemia. Not only did we not have any effective drugs, but we lacked the support facilities we have now. When I was a student and an intern at the University of Chicago, blood for transfusions was not only stored in glass bottles, but the glass bottles were protected from the outer environment through paper caps that were put over the open mouth and secured with a string. We would cut the string, pull off the paper, and then pour the blood through a funnel that contained surgical gauze that we had put into the funnel, trying not to touch it while we were doing so. Not surprisingly, patients tended to get fever and chills when they received this blood. The blood bank personnel claimed that the fever and chills were most marked in July and August, and that when the interns learned how to pour the blood without getting their thumbs in the way, the number of reactions decreased. Whether or not this was true, I don't know; but these patients had a difficult time, and we had a very difficult time taking care of them. There were occasional patients who did do very well, just as Gloor's patient. One patient, whom I inherited when I came to the City of Hope in 1959, had been treated the previous year by my colleague, Jesse Steinfeld. He had been given what was then the standard treatment for acute myelogenous leukemia: 6-MP and corticosteroids. He entered a complete remission and I did not administer maintenance therapy because I didn't know that was what I was supposed to do. I followed him for 20 years and he never relapsed. However, there was no question that his blood films were typical of acute granulocytic leukemia. As a matter of fact, at the time that I decided to start the marrow transplantation program at the City of Hope in 1978, I reviewed all of our adult patients with acute leukemia. Each year, there was one patient who was still alive and free of disease; even with the relatively primitive treatments we had available at that time, there were some patients who did survive acute leukemia.
In the middle 1970s, Don Thomas first began to present his data on the treatment of acute leukemia with marrow transplantation. At one meeting I recall his presenting particularly impressive data that showed a salvage rate of not 2% or 1%, Leukemia but actually of over 15%. 8 In retrospect, it is interesting how most hematologists responded to these data. The attitude was: 'look what he put them through for only a few survivals'. It was astonishing to me that even a few of them had survived, and even more surprising when one considered a subgroup of patients that he called good risk patients (although today we wouldn't call them that because they were all in relapse). What made bone marrow transplantation possible in large part was the unswerving commitment to this approach by Don and by his colleagues. There was, however, other technology that had to be developed to make it possible: infection control, tissue typing, various kinds of chemotherapy, immunosuppression, and transfusion support. These have gradually evolved as the standard support that we are able to offer and that have gradually improved the outcome.
I would like to comment very briefly about the issue of transfusion support, particularly with respect to platelets. Jacob (Rowe) pointed out earlier how many things we do really have no factual support. It is interesting that in the 1970s and early 1980s, most young hematologists adhered rigidly to the rule that if a patient had a platelet count under 20 000 a platelet transfusion had to be given. My earlier experience, before the introduction of platelet transfusions by Jay Freireich and his colleagues, was that patients could have much lower platelet counts and not bleed. Accordingly, we carried out a study at the City of Hope to determine whether this was true. We had great difficulty persuading the fellow who was involved in the study because he thought it would be dreadfully dangerous to allow platelet counts to fall below 20 000. We finally convinced him that this was both ethical and well worth doing, and we divided patients with acute myeloid leukemia randomly into those who received platelets prophylactically and those who received them for specific indications, which included bleeding or a rapid drop in the platelet count. There were two deaths from CNS bleeding. Both were in the prophylactic group. As expected, twice as many platelets were given to patients receiving prophylactic platelets than those who received them for specific indications. However, the average number of units of packed red blood cells was only very slightly, not statistically significantly, greater in the patients who received platelets only for specific indications, indicating that there was little effect on blood loss. The additional platelets patients received prophylactically certainly put them at risk, particularly with respect to hepatitis, since at that time there were no tests for hepatitis B or hepatitis C. The platelets were from pools so many of these patients who survived did get hepatitis. We concluded from these studies that, although the use of platelets in the prophylactic group was double that of the specific indication group, there were no differences in the number of deaths from all causes; the two deaths that occurred from CNS bleeding fortuitously occurred in the prophylactic group. It's interesting to look back to try to understand where this 20 000 platelet count rule originated. 10 It began with a classic paper by Jay Freireich in which he showed the relationship between the platelet count and severe bleeding. 11 How a 20 000 threshold was derived from his data is difficult to see, but this is the paper that everyone cites. They tend to forget the work of Slichter and Harker, 12 who showed that GI bleeding really began at platelet counts below 5000 per l. It is particularly interesting that Jay himself, who had written the paper that was so widely cited to support the use of a 20 000 trigger, had suggested in 1968 that prophylactic platelets were worth giving when the platelet count was below 10 000, not 20 000. Nonetheless, even in 1987, a consensus conference concluded with an ambiguous statement suggesting that perhaps physicians did not have to adhere to the 20 000 threshold. Fortunately, by now practice has changed and most of us really only use platelets when we need them.
I was fortunate enough to be able to attract Karl Blume to work with me in establishing a marrow transplantation program at the City of Hope. To state that the results were encouraging is an understatement. As I went through my slides to prepare this presentation, I found one that focused on the first dozen or so patients that we treated. I dare say that the data look as good as any that have been shown at this meeting today. 13 Why did we do so well? Well, I think partly because Karl Blume was an excellent physician, although I know that the other studies have been done with excellent physicians as well; partly because the patients were a very good group and, although not children, they were younger adults; and most importantly perhaps because we were very lucky in the patients that we happened to transplant initially. Actually, when this study matured, and with the addition of many more patients, the plateau declined to about 60%. I would point out that these results, reported in 1981, are not very different from the results we're observing today. Using the treatment of that day, there seemed to be a clear advantage of transplantation over chemotherapy alone.
I'd like to use the remaining few minutes to make some predictions. As has been attributed to both Yogi Berra and Dan Quayle, 'Predictions are always risky, especially those about the future'. In that context, I can share with you a few thoughts I have of opportunities on the horizon that may help us to do better in the treatment of this disease. We really need better stem cells. Being able to obtain the stem cells from peripheral blood has been an advance, but what we really would like to have are universal stem cells. These would be stem cells that we can order from the pharmacy and that can be given to everyone, not just for the person who is HLA matched. This means being able to remove the immunologic targets of stem cell rejection. One could also hope for conditionally immortal stem cells; that is, stem cells that can proliferate, so one can give a few thousand and they can expand to form millions of stem cells. Obviously the expansion of these cells has to be conditional because, if they can't be shut off, then we will be giving leukemia to a patient with leukemia.
It also would be very valuable to have the capacity to direct stem cells into a specific lineage. If the patient is doing quite well with respect to their granulocyte count, then the physician might like to target the platelet count; the patient could be given a drug that would make the stem cells understand that the formation of platelets are their mission for today. There are techniques that may be used to accomplish this aim, and I think perhaps it will be possible over the next few decades to implement them. One of these is the technique of turning on genes with small molecules; the one that's been used most is tetracycline. Basically, two constructs are placed into the cell, in this case, the stem cell, and these constructs confer sensitivity to activation by a small molecule of the gene that has been selected. 14 A second really very exciting prospect is that of harvesting autologous hematopoietic stem cells from tissues other than blood or marrow. Within the last year, there have been two reports, one dealing with neuroblasts, 15 the other with myoblasts. 16 Cells derived from muscle and from brain rather convincingly function as hematopoietic stem cells. If these data can be confirmed, we will need to discard the fixed notion that a hematopoietic stem cell has to come from the marrow. Cells derived from nonhematopoietic tissues presumably would not have the mutations that make the hematopoietic stem cell malignant. Thus one could take a muscle biopsy on a patient with leukemia, grow up the myoblasts in that muscle, and then allow them to differentiate into hematopoietic stem cells, stem cells that are now autologous, but completely free of the mutations causing malignancy. Another very recent exciting development is the regulation of genes by synthetic zinc finger proteins. This is based largely on work done by one of my colleagues at Scripps, Dr Carlos Barbas, who has, along with colleagues, basically decoded the sequence that is required to bind zinc finger to a DNA sequence. 17 An amino acid sequence that binds a very specific nucleotide sequence can now be designed. One can attach the zinc finger protein to a repression domain and turn off a gene, for example, an oncogene or an oncovirus. Attaching, instead, an activation domain to the zinc finger will allow one to turn on the target gene. Domains attached to zinc fingers can also be used to cleave DNA or to integrate a new segment of DNA into a gene. From the point of view of treating leukemia, it may be that turning off the original mutation event would allow the cells to revert to normal. All one would need to do is to make the right zinc finger protein.
How do you get these proteins into cells? The use of gene therapy would be a problem because the construct would have to be transduced into every single cell. But it is possible that some of these proteins may be made to permeate into cells, possibly using a permease made by HIV virus. Possibly, too, more efficient methods of transduction will be developed or this work could be extended to make small molecules that permeate cells and mimic the zinc fingers, binding to specific DNA sequences.
In summary, in the first 100 years after the description of leukemia, it was regarded as invariably fatal. It seems likely, however, that in retrospect, there were some cures. The implementation of combination chemotherapy and of stem cell transplantation has greatly improved the outlook. We might hope that with better understanding of molecular pathogenesis and the development of methods of manipulating genes that the prognosis for this terrible disease will improve in the 21st century.
Thank you so much for your attention and for the honor of addressing this august group.
